Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 225Uterine Cervical Neoplasms 181Fallopian Tube Neoplasms 93Carcinoma, Ovarian Epithelial 85Endometrial Neoplasms 74Neoplasms 37Uterine Cervical Dysplasia 35Papillomavirus Infections 35Breast Neoplasms 26Peritoneal Neoplasms 25Vulvar Neoplasms 23Condylomata Acuminata 22Vaginal Neoplasms 18Recurrence 16Testicular Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 12Brenner Tumor 12Primary Myelofibrosis 11Multiple Myeloma 11Lymphoma, Non-Hodgkin 11Lymphoma, Mantle-Cell 11Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myeloid, Chronic-Phase 11Leukemia, Myeloid, Accelerated Phase 11Leukemia, Lymphocytic, Chronic, B-Cell 11Blast Crisis 11

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cervical Cancer Metastatic × Gynecologic × Clear all
NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Shanghai Jiatan Pharmatech Co., Ltd

Phase 3 Not yet recruiting
440 enrolled
Gynecologic

Cervical Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡